The Global Molecular Diagnostics market size was valued at USD 9.9 billion in 2018 and is anticipated to expand at a CAGR of 9.1% over the forecast period. Advancements in molecular diagnostics have enabled detection of various diseases that could possibly reduce social and economic burden in a country.
Technological advancements in molecular diagnostics are expected to significantly drive the market as they enable greater accuracy, portability, and cost-effectiveness.
According to WHO, in 2019, the average prevalence rate of hospital-acquired infections in Europe and U.S. was 7.1% and 4.5%, respectively. Molecular diagnostics play an important role in infectious disease testing as they provide effective and fast results. Hence, rising prevalence of infectious diseases and hospital-acquired infections is expected to drive the market over the forecast period.
Central laboratories dominated the market in terms of revenue share in 2018 owing to high procedure volume and extensive presence of ancillary support in terms of man power and infrastructure.
The point-of-care (PoC) segment is projected to exhibit the fastest CAGR during the forecast period. Growing demand for bedside patient care owing to a flourishing home healthcare market coupled with rising market penetration of decentralized healthcare establishments is one of the major factors that can be attributed to its rapid growth.
Genetic Diagnostic Labs is selecting partners for its US Expansion Plan. Several Clinics and Specialized Medical Offices throughout the country are being Certified and Approved to receive a laboratory unit. Now, with this exclusive investment opportunity, you can be a partner of one of them:
MAIN BENEFITS TO INVESTORS
ROI in less than a 1 year
Excellent return on investment
Possibility of expansion with new units
All Certification and Homologation processes on behalf of our company
No need to have knowledge or training in the medical field
Units ready to operate with our technical team
See more in video below